Cibc World Market Inc. reduced its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 40.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,655 shares of the medical instruments supplier’s stock after selling 25,179 shares during the quarter. Cibc World Market Inc.’s holdings in Becton, Dickinson and Company were worth $6,740,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Moneco Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 2.6% during the 3rd quarter. Moneco Advisors LLC now owns 2,071 shares of the medical instruments supplier’s stock valued at $371,000 after acquiring an additional 52 shares during the last quarter. Brown Lisle Cummings Inc. boosted its stake in shares of Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after buying an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. increased its position in Becton, Dickinson and Company by 12.3% during the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after acquiring an additional 56 shares during the last quarter. Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company by 0.7% during the 3rd quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock worth $1,601,000 after acquiring an additional 58 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC grew its holdings in Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 60 shares during the period. 86.97% of the stock is owned by institutional investors.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,310 shares of company stock worth $688,650 over the last 90 days. Insiders own 0.40% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on BDX
Becton, Dickinson and Company Stock Down 0.2%
Shares of NYSE:BDX opened at $212.19 on Friday. The firm has a market capitalization of $58.47 billion, a PE ratio of 51.25, a price-to-earnings-growth ratio of 3.56 and a beta of 0.22. The business has a 50 day simple moving average of $194.40 and a two-hundred day simple moving average of $170.85. Becton, Dickinson and Company has a 1 year low of $140.11 and a 1 year high of $220.36. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.87 and a quick ratio of 0.54.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $3.96 earnings per share. On average, equities analysts predict that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company declared that its Board of Directors has authorized a share repurchase plan on Thursday, November 5th that permits the company to buy back 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Share repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
Becton, Dickinson and Company Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be given a $1.06 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, December 10th. This represents a $4.24 annualized dividend and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Further Reading
- Five stocks we like better than Becton, Dickinson and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
